nemolizumab (Nemluvio)

following a full submission assessed under the orphan equivalent medicine process:

nemolizumab (Nemluvio®) is not recommended for use within NHSScotland.

Indication under review: for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.

In two double-blind, randomised, phase III studies, nemolizumab treatment resulted in statistically significant and clinically meaningful improvements in the severity of pruritis and PN lesions, compared with placebo.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.